XHKG
3347
Market cap6.84bUSD
Oct 09, Last price
44.56HKD
1D
0.77%
1Q
21.55%
IPO
-60.67%
Name
Hangzhou Tigermed Consulting Co Ltd
Chart & performance
P/E
51.96
P/S
6.75
EPS
0.73
Div yield, %
0.73%
Shrs. gr., 5y
1.51%
Rev. gr., 5y
16.44%
Revenues
6.83b
+3.48%
Net income
888m
+119.15%
CFO
1.12b
+1.92%
Dividend
Jun 18, 20260.14468 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Key people
Chairman of the Board · since 2019
Hao Wu
Co-President, Executive Director, Staff Elected Director · since 2025
Chengcheng Yang
Finance Director · since 2022
Zengyu Wen
Deputy General Manager, Director · since 2023
Xiaori Li
Secretary of the Board · since 2021
Xiaochun Cao
General Manager, Director · since 2022
Qiyu Liao
Independent Non-Executive Director · since 2020
Yuwen Liu
Independent Non-Executive Director · since 2024
Independent Non-Executive Director · since 2023
Headquarters & legal address
浙江省杭州市滨江区江南大道618号东冠大厦1502-1室
杭州市, ZJ 310000
CN
杭州市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||